Advancing the DLBCL Paradigm Sequencing Bispecifics in Optimizing Patient Care CME New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT Hybrid Register Now

https://na.eventscloud.com/website/98542/ Advancing the DLBCL Paradigm Sequencing Bispecifics in Optimizing Patient Care CME New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT Hybrid Register Now Join this engaging, interactive symposium exploring the rapidly evolving landscape of bispecific antibodies in diffuse large B-cell lymphoma (DLBCL). Leading international experts will dive into topline clinical evidence across second- and third-line settings and frontline horizons, evaluating pivotal trial data in transplant-ineligible and high-risk populations. Through real-world clinical case scenarios, the panel will debate treatment sequencing—weighing bispecifics against chimeric antigen receptor (CAR) T-cell therapy, individualizing care based on patient fitness and geographic access, and assessing impacts on T-cell fitness. Furthermore, faculty will address key practicalities for integrating bispecific therapies into community practice, from managing safety and treatment logistics to streamlining care coordination and patient pathways. Walk away with concrete solutions to optimize sequencing, safety, and care delivery across the DLBCL continuum. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

Personalizing Prevention: Integrating Clinical Evidence Into Person-Centered Stroke Care CME COEX Convention & Exhibition Center Wednesday, 21 October 2026 | 11:45 - 12:45 KST Hybrid

Personalizing Prevention: Integrating Clinical Evidence Into Person-Centered Stroke Care CME COEX Convention & Exhibition Center Wednesday, 21 October 2026 | 11:45 - 12:45 KST Hybrid https://events.medscapelive.org/website/98716/?utm_campaign=edu_cardio%2Fneuro_457370.06a_regpage&utm_source=edu&utm_theraputic_area=1900&utm_medium=em&utm_content=int An engaging and interactive symposium in which leading experts in the field of stroke will discuss a novel approach to secondary stroke prevention. Using patient case examples and hearing from a stoke survivor, the experts will provide insights into the data supporting the use of FXIa inhibitors to prevent secondary stroke occurrence in high-risk patients without increasing their risk of bleeding. Through interactive case reviews, audience polling, and patient vignettes, attendees will gain practical, precision-driven strategies to personalize care.

Antibody discovery moves toward de novo design From computationally designed repertoires to AI-driven specificity prediction and multispecific therapeutics, antibody researchers are developing new ways to design molecules for the biology they need to influence. Written byBree Foster, PhD and Andrea Corona

Antibody discovery moves toward de novo design From computationally designed repertoires to AI-driven specificity prediction and multispecific therapeutics, antibody researchers are developing new ways to design molecules for the biology they need to influence. Written byBree Foster, PhD and Andrea Corona https://www.drugdiscoverynews.com/antibody-discovery-moves-toward-de-novo-design-17541 What if researchers could design antibodies with specific biological functions rather than simply search for molecules that bind a target? That question ran through The Antibody Series 2026 (TAS 2026), where speakers explored how computational design, AI, and increasingly complex antibody formats could expand what these therapies can do. But the conference also underscored a persistent challenge. Mark van Dijk, Chief Scientific Officer at Fairjourney Biologics, told DDN that antibody technology may no longer be the main limitation. Instead, “the biology is the limitation.”

Scientists create off-the-shelf T cell cancer therapy from cord blood The new highly scalable therapy successfully slowed tumor growth in mouse models of solid tumors. Written byAllison Whitten, PhD

Scientists create off-the-shelf T cell cancer therapy from cord blood The new highly scalable therapy successfully slowed tumor growth in mouse models of solid tumors. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/scientists-create-off-the-shelf-t-cell-cancer-therapy-from-cord-blood-17543 T cell receptor (TCR) therapy has a major advantage over the more widely known CAR T cell therapy: it goes beyond the cell’s surface to target tumor proteins that lie inside a cell. This makes it a particularly enticing approach for solid tumors where most of the tumor proteins remain on the inside. Yet, TCR therapy falls prey to the same drawbacks as CAR T therapy — namely the fact that personalized treatments made from each individual’s cells can take weeks to engineer, and off-the-shelf approaches from healthy donors can lead to graft-versus-host disease (GvHD).

Hot Drinks Tied to Esophageal Cancer. Should Patients Worry? Frederik Joelving

https://www.medscape.com/viewarticle/hot-drinks-tied-esophageal-cancer-should-patients-worry-2026a1000z6e Drinking very hot beverages was associated with a threefold higher risk of developing esophageal squamous cell carcinoma (ESCC) than consuming warm beverages, suggested a large new study from the UK that has been making headlines across the globe. If the link is causal, consuming beverages “hot” instead of “very hot” could prevent an estimated 14% of new ESCC cases, or 440 cancers each year in the UK, researchers reported. The study of nearly 1 million people is consistent with previous research from countries such as Iran and China, where ESCC is much more common, and with the International Agency for Research on Cancer classification of beverages consumed above 65 °C (149 °F) as “probably carcinogenic” to humans based on limited epidemiologic and experimental evidence.

Six Cancer Therapies Move Toward Broader EU Use

https://www.medscape.com/viewarticle/six-cancer-therapies-move-toward-broader-eu-use-2026a1000z9g?ecd=WNL_trdalrt_pos1_ous_260923_etid8720513&uac=148436CN&impID=8720513 The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended indication extensions for six already authorized oncology and hematology medicines at its September 2026 meeting. Abiraterone Mylan (abiraterone acetate; Mylan Pharmaceuticals Limited), Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca), Keytruda (pembrolizumab; Merck Sharp & Dohme), Padcev (enfortumab vedotin; Astellas Pharma), Pepaxti (melphalan flufenamide; Oncopeptides AB), and Tecvayli (teclistamab; Janssen-Cilag International) were all backed for broader use, either by moving into earlier treatment settings or expanding the eligible patient population.

Fabry Disease: Is The Risk of Kidney Failure Being Properly Managed By Your Medical Team? (++++)

Fabry Disease: Is The Risk of Stroke or Heart Failure Being Properly Managed By Your Medical Team? Fabry Disease: What Symptoms Should Be Better Managed By Your Medical Team? Fabry Disease: Patients' Real-World Problems and How to Manage